Press release from Companies
Publicerat: 2024-12-10 19:05:17
Copenhagen, Denmark, 10 December 2024 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) hereby announces in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, the disclosure of participation by members of Curasight’s Board of Directors and Executive Management team in the warrant exercise conducted on December 5th 2024.
The following is an overview of the transactions relating to the T02 warrants:
| Name | Position | Aggregated volume | Price, DKK |
| Kirsten Drejer | Chair of the Board | 12,174 | 140,001.00 |
| Lars Trolle | Deputy chair of the Board | 5,000 | 57,500.00 |
| Charlotte Vedel Johansen | Board member | 8,695 | 99,992.50 |
| Ulrich Krasilnikoff | CEO & CFO, Board member | 43,479 | 500,008.50 |
| Andreas Kjær | CMO & CSO, Board member | 43,479 | 500,008.50 |
| Total | 112,827 | 1,297,510.50 |
For further information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.
